Business Context and Reporting Period
Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing text identifies the registrant as RXi Pharmaceuticals Corporation).
Filing Type: Form 8-K (Current Report)
Reporting Date: April 11, 2012 (Event Date: April 3, 2012)
Business Context: The company is a Delaware corporation headquartered in Worcester, Massachusetts, engaged in pharmaceutical development. This filing reports the entry into a material definitive agreement regarding financing.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt balances, or liquidity ratios. The document focuses exclusively on the amendment of a securities purchase agreement and convertible promissory notes.
Material Changes
- Agreement Amendment: On April 3, 2012, RXi entered into an amendment to a securities purchase agreement originally dated September 24, 2011.
- Parties Involved: The agreement is between RXi and investors Galena Biopharma, Inc., Tang Capital Partners, LP, and RTW Investments, LLC.
- Extension of Deadlines: The amendment extended the termination date for the securities purchase agreement to April 18, 2012. This is the date after which either party may terminate the agreement if the closing has not occurred.
- Note Maturity: The maturity date of outstanding convertible promissory notes held by the investors was also extended to April 18, 2012.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, earnings outlook, or general management commentary beyond the specific details of the agreement amendment.
Risks and Contingencies: The primary contingency identified is the potential termination of the securities purchase agreement if the closing does not occur by the new deadline of April 18, 2012. The filing does not explicitly list other risk factors.
Unusual Items: None reported in this specific filing.
Investor Verification Checklist
- Verify the status of the closing of the securities purchase agreement as of the April 18, 2012 deadline.
- Confirm the terms of the outstanding convertible promissory notes and whether they were converted or repaid following the extension.
- Review subsequent filings to determine if the agreement was terminated or if the transaction closed.
- Clarify the relationship between "RXi Pharmaceuticals Corporation" and "Phio Pharmaceuticals Corp." to ensure correct entity identification for financial analysis.